ClinicalTrials.gg
Active, not recruitingNCT04671862Updated Oct 19, 2026

Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis

An interventional study of Photobiomodulation in Mucositis Oral, Head and Neck Cancer and Radiation Dermatitis, sponsored by Ottawa Hospital Research Institute. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Prevention

How we know

Updated Oct 19, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of mucositis in patients treated with radiotherapy for head and neck cancer

Previous studies in head and neck cancer patients have shown that photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in Canada using this technique in routine practice, but this is recommended in International guidelines and widely used in Europe. The investigators therefore wish to implement this technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.

Read the detailed description

Introduction: Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of mucositis in patients treated with radiotherapy for head and neck cancer

Rationale: Previous studies in head and neck cancer patients have shown that photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in Canada using this technique in routine practice, but this is recommended in International guidelines and widely used in Europe. The investigators therefore wish to implement this technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.

Purpose/Objectives: Primary Objective Primary Objective

  • To determine the cumulative incidence of acute mucositis as defined by CTCAE version 2.0 for radiation induced mucositis (Appendix 1) during radiotherapy and for 1month following radiotherapy

Secondary Objectives

To determine the following during radiotherapy and for 24 months post-treatment

  • Rate of occurrence of acute radiation dermatitis
  • Pain scores
  • Opioid use
  • ESAS scores during and after RT
  • FACT-HN questionnaire scores
  • Late subcutaneous neck fibrosis
  • Late mucosal and skin telangiectasia

Study design/methodology:

This is single arm prospective cohort study of a single intervention (photobiomodulation) in patients with head and neck cancer for the prevention of oral mucositis.

Outcomes will be the following:

  • Rates of acute and late mucositis according to CTCAE version 2.0
  • Rates of acute and late dermatitis and fibrosis according to CTCAE version 5.0
  • Rates of late teleangiectasia
  • Pain scores as per Edmonton Symptom assessment scale (ESAS) and modified brief pain inventory
  • Rates of opioid use
  • FACT-HN scores
  • EQ5D scores

Anticipated public/scientific benefit:

This study aims to study the use of Photobiomodulation treatments for prevention of oral mucositis. This is recommended in international guidelines but not used in routine practice in Canada. The benefit of this study is to allow implemetation of this technique in the Canadian context in a controlled and evaluated manner. This will hopefully then allow further study and wider implementation of this technique both in Ottawa and in Canada

02

Conditions studied

  • Mucositis Oral
  • Head and Neck Cancer
  • Radiation Dermatitis
03

In context

Stomatitis

307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.

This study's planned enrollment of 25 is below the median of 60 across 277 interventional studies indexed under Stomatitis.

Browse Stomatitis studies →

Lead sponsor

Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years of age
  • Willing and able to understand and sign form approved by the institutional review board (IRB)
  • Histological diagnosis of head and neck cancer of the oral cavity with no evidence of macroscopic residual disease post-surgery (R0 or R1 resection) and no gross residual lymphadenopathy in the planned PBM treatment area
  • Planned treatment with radiotherapy or chemoradiotherapy to a dose of ≥ 50 Gy
  • Performance Status of 0 or 1
  • Intact oral mucosa (no visible ulceration, dehiscence or active infection

Exclusion criteria

Exclusion Criteria:

  • Gross macroscopic residual disease post surgery (R2 resection) or gross residual lymphadenopathy in the planned PBM treatment area
  • Prior radiotherapy to the Head and Neck including the oral or oropharyngeal mucosa.
  • Prior cytotoxic chemotherapy in the last 3 months
  • Diagnosis of photosensitive disorder (cutaneous porphyria, xeroderma pigmentosum, etc)
  • Concurrent administration of Cetuximab
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Photobiomodulation

    Parameters: combined 633nm and 870 nm @1000mW * 1 Treatment pre radiotherapy * 3 treatments weekly during radiotherapy

    Device: Photobiomodulation

Interventions

  • DevicePhotobiomodulation

    Parameters: combined 633nm and 870 nm @1000mW * 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start) * 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)

06

What researchers measure

Primary outcomes

  1. Rate of occurence of radiation mucositis

    CTCAE version 2.0

    Time frame: 7-14 days post radiotherapy

  2. Rate of occurence of radiation mucositis

    CTCAE version 2.0

    Time frame: 1 month post radiotherapy

  3. Rate of occurence of radiation mucositis

    CTCAE version 2.0

    Time frame: 3 months post radiotherapy

  4. Rate of occurence of radiation mucositis

    CTCAE version 2.0

    Time frame: 6 months post radiotherapy

  5. Rate of occurence of radiation mucositis

    CTCAE version 2.0

    Time frame: 12 months post radiotherapy

  6. Rate of occurence of radiation mucositis

    CTCAE version 2.0

    Time frame: 24 months post radiotherapy

Secondary outcomes

  1. Brief Pain Inventory

    Pain questionnaire

    Time frame: 7-14 days post radiotherapy

  2. Brief Pain Inventory

    Pain questionnaire

    Time frame: 1 month post radiotherapy

  3. Brief Pain Inventory

    Pain questionnaire

    Time frame: 3 months post radiotherapy

  4. Brief Pain Inventory

    Pain questionnaire

    Time frame: 6 months post radiotherapy

  5. Brief Pain Inventory

    Pain questionnaire

    Time frame: 12 months post radiotherapy

  6. Brief Pain Inventory

    Pain questionnaire

    Time frame: 24 months post radiotherapy

  7. Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)

    Swallowing related quality of life

    Time frame: 7-14 days post-radiotherapy

  8. Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)

    Swallowing related quality of life

    Time frame: 1 month post-radiotherapy

  9. Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)

    Swallowing related quality of life

    Time frame: 3 months post-radiotherapy

  10. Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)

    Swallowing related quality of life

    Time frame: 12 months post-radiotherapy

  11. Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN)

    Swallowing related quality of life

    Time frame: 24 months post-radiotherapy

  12. EQ-5D

    General Quality of life questionnaire

    Time frame: 7-14 days post radiotherapy

  13. EQ-5D

    General Quality of life questionnaire

    Time frame: 1 month post radiotherapy

  14. EQ-5D

    General Quality of life questionnaire

    Time frame: 3 months post radiotherapy

  15. EQ-5D

    General Quality of life questionnaire

    Time frame: 6 months post radiotherapy

  16. EQ-5D

    General Quality of life questionnaire

    Time frame: 12 months post radiotherapy

  17. EQ-5D

    General Quality of life questionnaire

    Time frame: 24 months post radiotherapy

  18. Radiation dermatitis

    CTCAE version 5.0

    Time frame: 7-14 days post radiotherapy

  19. Radiation dermatitis

    CTCAE version 5.0

    Time frame: 1 month post radiotherapy

  20. Radiation dermatitis

    CTCAE version 5.0

    Time frame: 3 months post radiotherapy

  21. Radiation dermatitis

    CTCAE version 5.0

    Time frame: 6 months post radiotherapy

  22. Radiation dermatitis

    CTCAE version 5.0

    Time frame: 12 months post radiotherapy

  23. Radiation dermatitis

    CTCAE version 5.0

    Time frame: 24 months post radiotherapy

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.

Of 66 non-industry interventional studies with no phase under Stomatitis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's planned 66 months is above that.

Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 10 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2020
First posted
Dec 17, 2020
StartActual
Jun 1, 2021
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 19, 2026
Primary completion
Dec 31, 2025→Dec 31, 2026
Oct 19, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 31, 2025→Dec 31, 2026
    Study completion Dec 31, 2025→Dec 31, 2027
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04671862
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Jun 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion